Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Unge

Showing results (31-40 of 37) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 37 results.
Journal of Medicinal Chemistry|September 28, 1998
Design and synthesis of new potent C2-symmetric HIV-1 protease inhibitors. Use of L-mannaric acid as a peptidomimetic scaffoldM Alterman, M Björsne, A Mühlman, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 1, 1993
Human immunodeficiency virus type 1 (HIV-1) strains selected for resistance against the HIV-1-specific [2',5'-bis-O-(tert-butyldimethylsilyl)-3'-spiro- 5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide)]-beta-D-pentofurano syl (TSAO) nucleoside analogues retain sensitivity to HIV-1-specific nonnucleoside inhibitorsJ Balzarini, A Karlsson, A M Vandamme, et al.
Journal of Medicinal Chemistry|October 3, 1999
Design and fast synthesis of C-terminal duplicated potent C(2)-symmetric P1/P1'-modified HIV-1 protease inhibitorsM Alterman, H O Andersson, N Garg, et al.
Journal of Medicinal Chemistry|February 15, 2001
Synthesis and comparative molecular field analysis (CoMFA) of symmetric and nonsymmetric cyclic sulfamide HIV-1 protease inhibitorsW Schaal, A Karlsson, G Ahlsén, et al.
Journal of Medicinal Chemistry|October 9, 1999
Urea-PETT compounds as a new class of HIV-1 reverse transcriptase inhibitors. 3. Synthesis and further structure-activity relationship studies of PETT analoguesM Högberg, C Sahlberg, P Engelhardt, et al.
Acta Crystallographica. Section D, Biological Crystallography|September 27, 2006
Application of the use of high-throughput technologies to the determination of protein structures of bacterial and viral pathogensM J Fogg, P Alzari, M Bahar, et al.
Antiviral Research|December 18, 2007
The VIZIER project: preparedness against pathogenic RNA virusesB Coutard, A E Gorbalenya, E J Snijder, et al.
Pageof 4

Showing results (31-40 of 37) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
Journal of Medicinal Chemistry|September 28, 1998
Design and synthesis of new potent C2-symmetric HIV-1 protease inhibitors. Use of L-mannaric acid as a peptidomimetic scaffoldM Alterman, M Björsne, A Mühlman, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 1, 1993
Human immunodeficiency virus type 1 (HIV-1) strains selected for resistance against the HIV-1-specific [2',5'-bis-O-(tert-butyldimethylsilyl)-3'-spiro- 5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide)]-beta-D-pentofurano syl (TSAO) nucleoside analogues retain sensitivity to HIV-1-specific nonnucleoside inhibitorsJ Balzarini, A Karlsson, A M Vandamme, et al.
Journal of Medicinal Chemistry|October 3, 1999
Design and fast synthesis of C-terminal duplicated potent C(2)-symmetric P1/P1'-modified HIV-1 protease inhibitorsM Alterman, H O Andersson, N Garg, et al.
Journal of Medicinal Chemistry|February 15, 2001
Synthesis and comparative molecular field analysis (CoMFA) of symmetric and nonsymmetric cyclic sulfamide HIV-1 protease inhibitorsW Schaal, A Karlsson, G Ahlsén, et al.
Journal of Medicinal Chemistry|October 9, 1999
Urea-PETT compounds as a new class of HIV-1 reverse transcriptase inhibitors. 3. Synthesis and further structure-activity relationship studies of PETT analoguesM Högberg, C Sahlberg, P Engelhardt, et al.
Acta Crystallographica. Section D, Biological Crystallography|September 27, 2006
Application of the use of high-throughput technologies to the determination of protein structures of bacterial and viral pathogensM J Fogg, P Alzari, M Bahar, et al.
Antiviral Research|December 18, 2007
The VIZIER project: preparedness against pathogenic RNA virusesB Coutard, A E Gorbalenya, E J Snijder, et al.
Pageof 4